Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 10/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839037 | 0.93 | ACHE (0.53) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL4830098 | 0.92 | ACHE (0.54) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL4837257 | 0.90 | ACHE (0.52) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL4830090 | 0.89 | ACHE (0.52) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL4838780 | 0.83 | HTR2A (0.54) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL4837536 | 0.81 | HTR2A (0.54) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL4838263 | 0.80 | HSD11B1 (0.54) | HTR2ADRD2SLC6A4HTR7HTR1A | |
| SCHEMBL4839049 | 0.79 | HTR2A (0.53) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL4830006 | 0.78 | HTR2A (0.54) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL4830089 | 0.78 | HTR2A (0.54) | ACHEHTR2ADRD3DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | claimed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | claimed |
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | KCNJ2, KCNK2, KCNJ11 | ACHE 3053/4885HTR2A 894/4885DRD3 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.